Today, December 6, 2024, INIFY Laboratories AB, org. no. 559345-4431 (the "Company") held an extraordinary general meeting. A total of 28,168,336 shares were represented at the general meeting, which corresponds to 62.3 percent of the total number of shares and votes in the Company. Below is a summary of the resolution that were made. The extraordinary general meeting resolved, with the requisite majority, in accordance with the Board of Directors' previously published proposal.

Issue authorization

The general meeting resolved, in accordance with the Board of Directors' proposal, to authorize the Board of Directors to, on one or more occasions prior to the next annual general meeting, with or without preferential rights for the Company's shareholders and with or without provision for contribution in kind, set-off or other conditions, resolve on share issues. The total number of shares that may be issued pursuant to the authorization shall not be limited in any other way than what follows from the limitations of the share capital and the number of shares in the Articles of Association at any given time.

The purpose of the authorization is to be able to carry out the directed share issue and the subsequent repair issue that the Company intends to carry out and which was announced by the Company on November 15, 2024.

Complete resolution

Complete documentation of the resolution made at the general meeting are available on www.inify.com.

For further information, contact:
Ann-Charlotte Linderoth, CFO
E-mail: ann-charlotte.linderoth@inify.com

About Inify Laboratories AB

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision (https://www.contextvision.com/), with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.